Morning...there are signs this is stablizing...both my CRDL and WMT calls are green this morning
Im finding more and more playing options
are the way to go if careful
Im finding more and more playing options
are the way to go if careful
Recent CRDL News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/14/2026 11:29:43 AM
- Cardiol Therapeutics to Highlight MAVERIC Phase III Trial and Recently Published ARCHER Results in Live Interview with Barchart • Newsfile • 04/14/2026 11:27:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/10/2026 05:13:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/01/2026 11:29:42 AM
- Cardiol Therapeutics Announces Year-End 2025 Update on Operations • Newsfile • 04/01/2026 11:27:00 AM
- Form 40-F - Registration statement [Section 12] or Annual Report [Section 13(a), 15(d)] • Edgar (US Regulatory) • 03/31/2026 08:47:59 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/25/2026 12:39:50 PM
- Cardiol Therapeutics to Present at TD Cowen 46th Annual Health Care Conference • Newsfile • 02/25/2026 12:27:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/10/2026 12:32:59 PM
- Cardiol Therapeutics' ARCHER Phase II Study Results Published in ESC Heart Failure • Newsfile • 02/10/2026 12:27:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/02/2026 09:01:14 PM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 01/30/2026 09:01:11 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/26/2026 06:12:38 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/23/2026 02:26:12 PM
- Cardiol Therapeutics Announces Closing of Bought Deal Financing and Full Exercise of Over-Allotment Option for Gross Proceeds of $14.85 Million • Newsfile • 01/23/2026 02:16:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/16/2026 01:57:00 PM
- Cardiol Therapeutics Announces Bought Deal Financing for Gross Proceeds of $13.5 Million • Newsfile • 01/16/2026 01:46:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/13/2026 12:30:13 PM
- Cardiol Therapeutics Achieves Key 50% Patient Enrollment Milestone in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis • Newsfile • 01/13/2026 12:27:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/01/2025 01:05:13 PM
- New Data from the Phase II ARCHER Trial Demonstrate CardiolRx(TM) Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions • Newsfile • 12/01/2025 12:27:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/13/2025 09:24:02 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/13/2025 12:57:02 PM
- Cardiol Therapeutics Receives U.S. Patent Allowance Broadly Protecting its Heart Drugs to Late 2040 • Newsfile • 11/13/2025 12:45:00 PM
- Form SUPPL - Voluntary Supplemental Material by Foreign Issuers [Section 11(a)] • Edgar (US Regulatory) • 11/05/2025 10:30:14 PM
